Compare Natco Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA LUPIN NATCO PHARMA/
LUPIN
 
P/E (TTM) x 15.5 49.2 31.6% View Chart
P/BV x 3.1 2.5 121.0% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NATCO PHARMA   LUPIN
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
LUPIN
Mar-19
NATCO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,080986 109.5%   
Low Rs671720 93.2%   
Sales per share (Unadj.) Rs592.1369.5 160.3%  
Earnings per share (Unadj.) Rs188.413.4 1,405.5%  
Cash flow per share (Unadj.) Rs206.337.4 552.0%  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.6303.7 274.5%  
Shares outstanding (eoy) m36.90452.49 8.2%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.52.3 64.0%   
Avg P/E ratio x4.663.6 7.3%  
P/CF ratio (eoy) x4.222.8 18.6%  
Price / Book Value ratio x1.12.8 37.4%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,311386,064 8.4%   
No. of employees `0004.817.7 27.3%   
Total wages/salary Rs m3,25631,513 10.3%   
Avg. sales/employee Rs Th4,522.59,453.8 47.8%   
Avg. wages/employee Rs Th674.01,782.0 37.8%   
Avg. net profit/employee Rs Th1,439.0343.0 419.6%   
INCOME DATA
Net Sales Rs m21,848167,182 13.1%  
Other income Rs m4043,640 11.1%   
Total revenues Rs m22,252170,822 13.0%   
Gross profit Rs m9,28428,822 32.2%  
Depreciation Rs m66210,850 6.1%   
Interest Rs m1543,078 5.0%   
Profit before tax Rs m8,87218,534 47.9%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1,9209,017 21.3%   
Profit after tax Rs m6,9526,066 114.6%  
Gross profit margin %42.517.2 246.5%  
Effective tax rate %21.648.7 44.5%   
Net profit margin %31.83.6 877.0%  
BALANCE SHEET DATA
Current assets Rs m21,307138,536 15.4%   
Current liabilities Rs m5,92061,299 9.7%   
Net working cap to sales %70.446.2 152.4%  
Current ratio x3.62.3 159.3%  
Inventory Days Days7384 87.4%  
Debtors Days Days107112 94.7%  
Net fixed assets Rs m14,986127,516 11.8%   
Share capital Rs m369905 40.8%   
"Free" reserves Rs m30,353136,517 22.2%   
Net worth Rs m30,760137,422 22.4%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m37,151279,494 13.3%  
Interest coverage x58.67.0 834.8%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.6 98.3%   
Return on assets %19.13.3 584.7%  
Return on equity %22.64.4 512.1%  
Return on capital %29.38.9 329.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32259,414 17.4%   
Fx outflow Rs m2,97822,282 13.4%   
Net fx Rs m7,34337,132 19.8%   
CASH FLOW
From Operations Rs m4,63616,660 27.8%  
From Investments Rs m-11,155-32,825 34.0%  
From Financial Activity Rs m6,5097,441 87.5%  
Net Cashflow Rs m-18-8,724 0.2%  

Share Holding

Indian Promoters % 52.0 46.6 111.7%  
Foreign collaborators % 1.5 0.2 735.0%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 31.9 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.1 257.4%  
Shareholders   25,395 98,259 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS